Welcome to our dedicated page for Leap Therapeutic news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutic stock.
The news feed for Leap Therapeutics, Inc. (historically Nasdaq: LPTX) captures the company’s transition from a biotechnology issuer focused on targeted and immuno-oncology therapeutics to the renamed Cypherpunk Technologies Inc. with an added digital asset treasury strategy. Press releases describe how the public company changed its name to Cypherpunk Technologies Inc., plans to trade under the ticker CYPH, and intends to acquire and hold Zcash (ZEC) while continuing cancer drug development through a subsidiary that will take the Leap Therapeutics name.
News items cover clinical and preclinical updates for the oncology pipeline, including detailed results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in microsatellite stable colorectal cancer, and preclinical findings for FL-501, a GDF-15–targeting monoclonal antibody associated with cancer cachexia research. Releases describe statistically significant benefits in DKK1-high colorectal cancer subgroups and activity of FL-501 in animal models of cachexia and chemotherapy-induced weight loss.
Investors can also follow strategic and corporate developments such as the initiation of a process to explore strategic alternatives for sirexatamab and FL-501, workforce reductions and restructuring to conserve cash, and the closing of a private placement led by Winklevoss Capital to fund the digital asset treasury strategy. Additional news highlights governance changes, including new board appointments linked to the financing, and the company’s rationale for focusing on Zcash as a privacy-preserving digital asset.
This page brings together these oncology, digital asset, financing, and governance announcements so readers can review how the historical LPTX issuer evolved into Cypherpunk Technologies Inc. and how its cancer programs and Zcash-focused treasury strategy are described in official communications.
Leap Therapeutics, a biotechnology firm listed on Nasdaq under LPTX, announced that its CEO, Douglas E. Onsi, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 3:00 p.m. Eastern Time. The presentation will be available via webcast on the company's Investors page. Leap is focused on developing targeted immuno-oncology therapeutics, with its leading candidate, DKN-01, in trials for various cancers.
Leap Therapeutics (Nasdaq: LPTX) has announced the expansion of its leadership team, appointing Jason S. Baum as Vice President, Head of Translational Medicine, and Christine M. Granfield as Vice President, Head of Regulatory Affairs and Quality. These appointments bring over 37 years of combined industry experience, with Baum's expertise in precision medicine and Granfield's extensive regulatory background expected to enhance Leap's development of its lead candidate, DKN-01, targeting various cancers. The company focuses on advancing innovative therapeutics in oncology.
Leap Therapeutics, Inc. (Nasdaq:LPTX) reported its Q2 2020 financial results, highlighting a net loss of $6.5 million, down from $8.4 million in Q2 2019. The company completed a $51.75 million public offering and presented positive DKN-01 clinical trial data, showing responses in endometrial and carcinosarcoma patients. DKN-01 received Orphan Drug Designation for gastric and gastroesophageal junction cancers, enhancing its development prospects. Cash and marketable securities stood at $64.9 million as of June 30, 2020.
Leap Therapeutics (NASDAQ: LPTX) announced the closing of an additional 3,375,000 shares in a public offering, resulting in approximately $51.75 million in gross proceeds. This follows the underwriters' full exercise of their option to purchase additional shares. The offering was managed by Piper Sandler & Co. and Raymond James & Associates, among others. Leap focuses on developing targeted and immuno-oncology therapeutics, with DKN-01 as its leading candidate in clinical trials for multiple cancer types.
Leap Therapeutics, Inc. (NASDAQ:LPTX) has successfully closed a public offering of 20,250,000 shares of common stock and pre-funded warrants for an estimated gross amount of $45 million. The offering, managed by Piper Sandler & Co. and Raymond James & Associates, utilized an effective shelf registration statement previously filed with the SEC. These funds will support Leap's development of targeted and immuno-oncology therapeutics, particularly its lead candidate DKN-01, currently in clinical trials for various cancers. Detailed offering materials are available on the SEC website.
Leap Therapeutics (NASDAQ:LPTX) announced the pricing of a public offering of common stock at $2.00 per share and pre-funded warrants at $1.999 each, aiming to raise approximately $45 million before expenses. The offering is expected to close around June 22, 2020. Proceeds will fund the development of DKN-01, manufacturing of clinical trial materials, and general corporate purposes. The offering is being managed by Piper Sandler & Co. and Raymond James Associates, Inc., with an option for underwriters to purchase an additional 3,375,000 shares.
Leap Therapeutics, Inc. (NASDAQ:LPTX) has initiated an underwritten public offering of common stock and pre-funded warrants. This offering includes a 30-day option for underwriters to purchase an additional 15% of the securities. The proceeds will primarily fund the development of DKN-01, manufacturing of trial materials, and general corporate purposes. The offering is subject to market conditions, with no guarantee of completion. The securities will be issued under an effective shelf registration statement with the SEC.